Highlight
Sentinel lymph node biopsy (SLNB) has limited influence on adjuvant treatment decisions in women aged 65 years or older with clinical T2N0 hormone receptor-positive/HER2-negative breast cancer. Chemotherapy choices were primarily driven by genomic assays rather than nodal status, and most node-positive patients did not receive regional nodal irradiation. These results support a selective, individualized approach to axillary staging in this patient group.
